Clinical trials for Lung cancer
272 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
1
Targeted therapy
Systemic Treatment-Naive
Janssen
Janssen
Phase 3
Lung cancer
#NCT06119581
#2023-503412-33-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
None
Systemic Treatment-Naive
BRAF
EGFR
HER2
MET
NTRK-1/2/3
RET
ROS-1
Immunotherapy
Chemotherapy
Targeted therapy
Hôpital Robert Schuman - UNEOS (Vantoux), CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Hôpital Louis Pradel (Bron ), Centre Léon Bérard (Lyon), Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil (Strasbourg) (and 11 more...)
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT06712355
#2024-515765-34-00
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
None
Systemic Treatment-Naive
Targeted therapy
Bispecific T-cell engager antibodies
CHU Caen Normandie (Caen)
BioNTech SE
Phase 3
Lung cancer
#NCT07099898
#2025-521627-78
SCLC (Small Cell Lung Cancer)
Locally Advanced
Metastatic
1
Immunotherapy
Chemotherapy
Hôpital Ambroise-Paré AP-HP (Boulogne-Billancourt)
GlaxoSmithKline
Phase 3
Lung cancer
#NCT06890598
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
KRAS G12C
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Chemotherapy
Radiotherapy
ALK
EGFR
Hôpital de la Timone AP-HM (Marseille), Centre Hospitalier Universitaire de Grenoble (La Tronche), Hôpital Européen Georges Pompidou - AP-HP (Paris), Hôpital Louis Pradel (Bron ), Gustave Roussy (Villejuif) (and 9 more...)
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT06890598
NSCLC (Non-Small Cell Lung Cancer)
Localized
Locally Advanced
KRAS G12C
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Surgery
Immunotherapy
Chemotherapy
ALK
EGFR
Gustave Roussy (Villejuif), Hôpital Louis Pradel (Bron ), Centre Hospitalier Universitaire de Toulouse (Toulouse), Institut Curie - Paris (Paris), Hôpital Robert Schuman - UNEOS (Vantoux) (and 9 more...)
Eli Lilly et compagnie
Phase 3
Lung cancer
#NCT07190248
#2024-514500-14-00
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
Systemic Treatment-Naive
Centre Hospitalier Métropole Savoie (Chambéry), CHRU de Nancy - Hôpitaux de Brabois (Vandœuvre-lès-Nancy), Hôpital Saint-Joseph (Paris), CHU Caen Normandie (Caen), Hôpital Européen de Marseille (Marseille) (and 2 more...)
Merck Sharp & Dohme LLC